Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $39.7 million.

  • Celldex Therapeutics' Accumulated Expenses rose 4081.34% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year increase of 4081.34%. This contributed to the annual value of $33.8 million for FY2024, which is 5362.48% up from last year.
  • As of Q3 2025, Celldex Therapeutics' Accumulated Expenses stood at $39.7 million, which was up 4081.34% from $28.4 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Accumulated Expenses ranged from a high of $39.7 million in Q3 2025 and a low of $7.0 million during Q1 2021
  • Over the past 5 years, Celldex Therapeutics' median Accumulated Expenses value was $12.8 million (recorded in 2022), while the average stood at $17.7 million.
  • Per our database at Business Quant, Celldex Therapeutics' Accumulated Expenses soared by 151.61% in 2023 and then skyrocketed by 8707.06% in 2024.
  • Celldex Therapeutics' Accumulated Expenses (Quarter) stood at $12.0 million in 2021, then rose by 6.96% to $12.8 million in 2022, then surged by 71.63% to $22.0 million in 2023, then soared by 53.62% to $33.8 million in 2024, then increased by 17.35% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $28.4 million for Q2 2025, and $25.5 million during Q1 2025.